Eli Lilly (LLY) said Wednesday that its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first head-to-head clinical trial. Eli Lilly stock edged higher in early trade while Novo Nordisk (NVO) was little changed.
Lilly's Zepbound reduced patients' weight by 20.2% after 72 weeks, or about 50 pounds. That's vs. 13.7%, or roughly 33 pounds, for Novo Nordisk drug Wegovy.
↑ XAlso, nearly 32% of Zepbound patients lost at least a one-fourth of their body weight vs. 16% for Wegovy takers.
The Eli Lilly-spurred study results are not a shock, given that separate studies have signaled that its Zepbound bests Novo's Wegovy on weight loss.
Zepbound's active ingredient is tirzepatide, a dual GIP and GLP-1 receptor agonist. Wegovy's semaglutide is a GLP-1 receptor agonist.
In premarket trade, Eli Lilly stock rose 0.7%. Novo Nordisk stock was essentially flat.
YOU MAY ALSO LIKE:
Why This IBD Tool Simplifies The Search For Top Stocks
Catch The Next Big Winning Stock With MarketSurge
Best Growth Stocks To Buy And Watch
IBD Digital: Unlock IBD's Premium Stock Lists, Tools And Analysis Today
Futures Rise On Earnings; 3 Hot AI Stocks
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.